Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, ba...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, Laura Vangeel, Franck Touret, Ayorinde Adehin, Palang Chotsiri, Maxime Cochin, Caroline S. Foo, Dirk Jochmans, Seungtaek Kim, Léa Luciani, Grégory Moureau, Soonju Park, Paul-Rémi Pétit, David Shum, Thanaporn Wattanakul, Birgit Weynand, Laurent Fraisse, Jean-Robert Ioset, Charles E. Mowbray, Andrew Owen, Richard M. Hoglund, Joel Tarning, Xavier de Lamballerie, Antoine Nougairède, Johan Neyts, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2022-08-01
סדרה:	Microorganisms
נושאים:	COVID-19 drug repurposing translational medicine pandemics clinical trials
גישה מקוונת:	https://www.mdpi.com/2076-2607/10/8/1639
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!